Related Experiment Videos
Cardiovascular, Kidney, Liver, and Metabolic Interactions in Heart Failure: Breaking Down Silos
Chang Jie Mick Lee1,2, Leah B Kosyakovsky3, Muhammad Shahzeb Khan4,5
1Cardiovascular Metabolic Disease Translational Research Programme, National University of Singapore, Yong Loo Lin School of Medicine, Centre for Translational Medicine, Singapore (C.J.M.L., R.S.-Y.F.).
Insights
Metabolic diseases significantly impact heart failure (HF) epidemiology, particularly HF with preserved ejection fraction. Understanding multiorgan interactions is crucial for managing complex HF cases and developing targeted therapies.
Area of Science:
- Cardiology
- Metabolic Diseases
- Nephrology
- Hepatology
Background:
- Rising metabolic disease burden correlates with shifts in heart failure (HF) epidemiology, including increased HF with preserved ejection fraction.
- Extracardiac factors and interorgan communication are critical in HF pathophysiology and heterogeneity.
- Traditional approaches examining single comorbidities may miss shared mechanisms and bidirectional relationships in HF.
Purpose of the Study:
- To review multiorgan interactions (cardiac, kidney, liver, metabolism) in HF development and progression.
- To propose research strategies, including multiomics and machine learning, for understanding HF in the context of multiple organ disease.
- To provide recommendations for clinical practice regarding screening and management of multiorgan involvement in HF.
Main Methods:
- Literature review of multiorgan interactions in HF.
- Analysis of preclinical HF models and their insights into multiorgan disease.
- Review of current clinical trials and therapeutic agents targeting the cardiac-kidney-liver-metabolism axis.
Main Results:
- Multiorgan interactions significantly complicate HF development and progression.
- Advanced epidemiological approaches like multiomics and machine learning can better capture underlying mechanisms and interorgan crosstalk.
- Existing preclinical models have advanced understanding of multiorgan disease in HF subtypes.
Conclusions:
- A comprehensive understanding of cardiac, kidney, liver, and metabolic interactions is essential for managing HF.
- Clinical practice requires integrated screening and management strategies for multiorgan involvement in HF.
- Future clinical trials must be more inclusive, examining multimorbidity and incorporating multiorgan endpoints for greater clinical relevance.
Abstract:
Over the past few decades, the rising burden of metabolic disease, including type 2 diabetes, prediabetes, obesity, and metabolic dysfunction-associated steatotic liver disease, has corresponded with fundamental shifts in the landscape of heart failure (HF) epidemiology, including the rising prevalence of HF with preserved ejection fraction. It has become increasingly important to understand the role of extracardiac contributors and interorgan communication in the pathophysiology and phenotypic heterogeneity of HF. Whereas traditional epidemiological strategies have separately examined individual contributions of specific comorbidities to HF risk, these approaches may not capture the shared mechanisms and more complex, bidirectional relationships between cardiac and noncardiac comorbidities. In this review, we highlight the cardiac, kidney, liver, and metabolism multiorgan interactions and pathways that complicate HF development and progression and propose research strategies to further understand HF in the context of multiple organ disease. This includes evolving epidemiological approaches such as multiomics and machine learning which may better capture common underlying mechanisms and interorgan crosstalk. We review existing preclinical models of HF and how they have enhanced our understanding of the role of multiorgan disease in the development of HF subtypes. We suggest recommendations as to how clinical practice across multiple specialties should screen for and manage multiorgan involvement in HF. Finally, recognizing the advent of novel combinatorial therapeutic agents that may have multiple indications across the cardiac-kidney-liver metabolism continuum, we review the current clinical trials landscape. We specifically highlight a pressing need for the design of more inclusive trials that examine the contributions of multimorbidity and incorporate multiorgan end points, which we propose may lead to outcomes that are evermore clinically relevant today.
Related Concept Videos
Heart Failure V: Medical Management
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: Diuretics
Pathophysiology of Heart Failure
Cardiomyopathy V: Interprofessional Care
Heart Failure II: Pathophysiology